Aequus Pharmaceuticals Inc.
AQS.V
TSX
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 76.26% | 8.47% | 70.43% | 24.78% | 4.31% |
| Total Depreciation and Amortization | -100.00% | -5.71% | -5.22% | -6.18% | -6.56% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -57.02% | 1,885.96% | -116.00% | -30.08% | -27.69% |
| Change in Net Operating Assets | 215.50% | 74.24% | 143.87% | 136.29% | -158.85% |
| Cash from Operations | 93.43% | 105.71% | 91.43% | 47.21% | -45.89% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -89.84% | -51.70% | 10.00% |
| Total Debt Repaid | 202.15% | -2.15% | -6.30% | -8.55% | -8.55% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -91.68% | -106.77% | -93.98% | -55.62% | 8.12% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 91.18% | 86.97% | -58.64% | -122.50% | -230.10% |